Hamed Javan MD

Jewish General Hospital

Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.

dont miss

Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer

Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.

EVEN MORE SEMINARS

  • Odette Woods  <br >  AGSM, PgDipRNCM, RGN: Speaking at the Oncology Convention

    Odette Woods
    AGSM, PgDipRNCM, RGN

    Cancer Hopeline

    Empowering Cancer Patients to Optimal Treatment Outcomes and Prognosis

  • Hamed Javan MD: Speaking at the Oncology Convention

    Hamed Javan MD
    Jewish General Hospital

    Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer

  • Mr Richard Steyn: Speaking at the Oncology Convention

    Mr Richard Steyn
    UK Lung Cancer Coalition / University Hospitals Birmingham NHS Foundation Trust

    Doubling Five-Year UK Lung Cancer Survival to 25% by 2025

  • Khurum Khan: Speaking at the Oncology Convention

    Khurum Khan
    Royal Marsden NHS Foundation Trust

    Biomarkers of response and/or resistance to targeted therapies in refractory mCRC

  • Dr. Matthew Prime: Speaking at the Oncology Convention

    Dr. Matthew Prime
    Roche Diagnostics Information Solutions

    Personalized healthcare: Leveraging data to improve patient care through clinical decision support in oncology